jeudi 6 décembre 2018

Onco Actu du 6 décembre 2018

1. Biologie

Cancer researchers seek to harness mysterious DNA ‘super-enhancers’ [Nature]

1.4 Biologie - Technos

CRISPR Scientists Slam Methods Used on Gene-Edited Babies [The Scientist]

3.3 Prévention - Vaccins

Quebec’s change to HPV vaccine program divides experts [The Globe and Mail]

4.12 Biopsies liquides

Using water and gold, Australian researchers discover ‘universal cancer biomarker’ [FierceBiotech]

Holy grail cancer test? Hold on. Here’s what you need to know [HealthNewsReview]

New Universal Cancer Test Takes Only Ten Minutes. The Secret Ingredient? Gold. [Forbes]

‘Universal fingerprint’ in cancer DNA points to potential blood test. But it’s not ready for patients [Cancer Research UK]

Grail Launches New Early Cancer Detection Study, Refocuses Strategy to Multi-Cancer Test [Genome Web]

4.2 Dép., diag. & prono. - Génome

The UK has sequenced 100,000 whole genomes in the NHS [Genomics England]

5.1 Traitements - Pré-clinique

Mannose and Cancer [In the Pipeline]

5.10 Traitements - Essais

Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE Study) Halted [AbbVie]

AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff [EndPoints]

AbbVie halts late-stage trial for lung cancer drug Rova-T [Reuters]

5.12 Immunothérapies

A minor population of tumor infiltrating CD8+ T cells actually express tumor antigen specific TCR [NIHilist's Immunology]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

In CAR-T, manufacturing a hurdle Novartis has yet to clear [BiopharmaDive]

5.2 Pharma

AstraZeneca's Calquence found success in lymphoma. Will CLL follow? [FiercePharma]

5.7.1 SABCS-communiqués

Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment [Roche]


Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer [AACR]

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy [AACR]

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer [AACR]

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint [AACR]

5.8 ASH

At ASH, bispecific cancer therapies make a mark [BiopharmaDive]

3 questions leaving ASH [BiopharmaDive]

5.8.4 ASH - CAR T

Mayo Clinic researchers identify new strategies that may improve CAR-T cell therapy [Mayo Clinic]

5.8.6 ASH - Leucémies

Potential seen to tailor acute myeloid leukemia treatment [UW Medicine]

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia [NCI]

6.6 Publications

Plan S: Impact on Society Publishers [The Scholarly Kitchen]

6.7 DMP, Big Data & applis

U.K. sets out digital, data-driven plan to accelerate R&D [FierceBiotech]

6.9 Controverses

How sure are you of your result? Put a number on it [Nature]